Methods for diagnosing diseases and evaluating treatments therefor using PET
View Patent ↗The present invention relates to methods for determining whether a mammal has a disease, such as diabetes, using PET data analysis techniques. These methods include administering to a mammal a PET-compatible tracer, such as a radioligand specific for a vesicular monoamine transporter 2 (VMAT2) receptor, and measuring total functional β-cell capacity (volume) of the mammal's pancreas using PET data analysis techniques. Methods for tracking the efficacy of a treatment for diabetes, for evaluating the regeneration of β-cells in a pancreas, and for monitoring a patient with a transplanted pancreas are also provided.
1. A method of diagnosing diabetes in a patient comprising:
a. administering to a patient a positron emission tomography (PET)-compatible tracer, which tracer binds to a vesicular monoamine transporter 2 (VMAT2) receptor;
b. carrying out a PET scan of the patient; and
c. applying a PANG MAP method comprising a module selected from the group consisting of (i) Module 1, Module 2, and Module 3, and (ii) Module 1 and Module 3, to the PET scan data,
wherein Module 1 comprises identifying binding potential (BP) positive voxels extracted from the PET data and generating a functionally defined β-cell region of interest (ROI) time activity curve (TAC); Module 2 comprises applying a three-parameter multilinear reference tissue model (MRTM) and a two-parameter multilinear reference tissue model (MRTM2) to the ROI TAC data from Module 1 to identify BP positive voxels; and Module 3 comprises generating a frequency distribution plot from the BP positive voxels identified in Module 1 or 2, calculating a significant binding capacity (SBC), and comparing the SBC of the patient to the SBC of a control individual,
and wherein a SBC generated for the patient that is lower than a SBC of a control individual who does not have diabetes is indicative that the patient has diabetes, wherein SBC=Σ (individual voxel BP above predetermined significant value×voxel volume), and wherein the predetermined significant value is a BP value greater than 0.
2. The method according to claim 1 , wherein the PANC MAP method comprises carrying out Module 1, Module 2, and Module 3.
3. The method according to claim 1 , wherein the PANC MAP method comprises carrying out Module 1 and Module 3.
4. The method according to claim 1 , wherein the tracer is a radiolabeled analog of tetrabenazine.
5. The method according to claim 4 , wherein the radiolabeled analog of tetrabenazine is dihydrotetrabenazine (DTBZ).
6. The method according to claim 5 , wherein the radiolabeled DTBZ is 11 C-DTBZ or 18 F-DTBZ.
7. The method according to claim 1 , wherein the diabetes is type-1 diabetes.